The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
Open accessAbstract
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-human results using 177Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT). Methods: PTRT using 177Lu-FAP-2286 was performed in 11 patients with advanced adenocarcinomas of pancreas, breast, rectum and ovary after prior confirmation of uptake on 68Ga-FAP-2286/-FAPI-04- PET/CT. Results: Administration of 177Lu-FAP-2286 (5.8 ± 2.0 GBq; range, 2.4–9.9 GBq) was well tolerated, with no adverse symptoms or clinically detectable pharmacologic effects being noticed or reported in any of the patients. The whole-body effective doses were 0.07 ± 0.02 Gy/GBq (range 0.04 – 0.1). The mean absorbed doses for kidneys and red marrow were 1.0 ± 0.6 Gy/GBq (range 0.4 – 2.0) and 0.05 ± 0.02 Gy/GBq (range 0.03 – 0.09), respectively. Significant uptake and long tumor retention of 177Lu-FAP-2286 resulted in high absorbed tumor doses, e.g., 3.0 ± 2.7 Gy/GBq (range 0.5 – 10.6) in bone metastases. No grade (G) 4 adverse events were observed. G3 events occurred in 3 patients – 1 pancytopenia, 1 leukocytopenia and 1 pain flare-up; 3 patients reported pain-response. Conclusion:177Lu-FAP-2286 PTRT, applied in a broad spectrum of cancers, was relatively well-tolerated with acceptable side effects and demonstrated long retention of the radiopeptide. Prospective clinical studies are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citation68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H., Röhrich, M., Winter, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227967 · Cited by 1,464
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Lindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
Ronnov-Jessen, L., Petersen, O. W., & Bissell, M. J. (1996) · Physiological Reviews · doi:10.1152/physrev.1996.76.1.69 · Cited by 793
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
The role of stromal cancer-associated fibroblasts in pancreatic cancer
von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A., & Verma, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0448-5 · Cited by 389
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Watabe, T., Liu, Y., Kaneda-Nakashima, K., Shirakami, Y., Lindner, T., Ooe, K., Toyoshima, A., Nagata, K., Shimosegawa, E., Haberkorn, U., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233122 · Cited by 302
Jansen, K., Heirbaut, L., Cheng, J. D., Joossens, J., Ryabtsova, O., Cos, P., Maes, L., Lambeir, A.-M., De Meester, I., Augustyns, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300410d · Cited by 260
Varasteh, Z., Mohanta, S., Robu, S., Braeuer, M., Li, Y., Omidvari, N., Topping, G., Sun, T., Nekolla, S. G., Richter, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226993 · Cited by 256
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes
Bauer, S., Jendro, M. C., Wadle, A., Kleber, S., Stenner, F., Dinser, R., Reich, A., Faccin, E., Gödde, S., Dinges, H., et al. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2080 · Cited by 230
Schuberth, P. C., Hagedorn, C., Jensen, S. M., Gulati, P., van den Broek, M., Mischo, A., Soltermann, A., Jüngel, A., Marroquin Belaunzaran, O., Stahel, R., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-187 · Cited by 206
Kulkarni, H. R., Singh, A., Schuchardt, C., Niepsch, K., Sayeg, M., Leshch, Y., Wester, H.-J., & Baum, R. P. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170167 · Cited by 192
Self-citationWehrmann, C., Senftleben, S., Zachert, C., Müller, D., & Baum, R. P. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.325 · Cited by 177
Self-citationBrünker, P., Wartha, K., Friess, T., Grau-Richards, S., Waldhauer, I., Ferrara, C., Weiser, B., Majety, M., Runza, V., Niu, H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0647 · Cited by 145
Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., Schreckenberger, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088239 · Cited by 143
Fabre, M., Ferrer, C., Domínguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2238 · Cited by 126
Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000606 · Cited by 85
Schuchardt, C., Kulkarni, H., Prasad, V., Zachert, C., Müller, D., & Baum, R. P. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-27994-2_30 · Cited by 72
Self-citationMüeller, D., Breeman, W. A. P., Klette, I., Gottschaldt, M., Odparlik, A., Baehre, M., Tworowska, I., & Schultz, M. K. (2016) · Nature Protocols · doi:10.1038/nprot.2016.060 · Cited by 66
Zboralski, D., Osterkamp, F., Simmons, A. D., Bredenbeck, A., Schumann, A., Paschke, M., Beindorff, N., Mohan, A.-M., Nguyen, M., Xiao, J. J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.685 · Cited by 22
Self-citationSabet, A., Khalaf, F., Mahjoob, S., Zreiqat, A. A., Biersack, H., & Ezziddin, S. (2013) · Europe PMC (PubMed Central) · Cited by 6
Cited by
Radiotheranostics in oncology: current challenges and emerging opportunities
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00652-y · Cited by 414
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Zboralski, D., Hoehne, A., Bredenbeck, A., Schumann, A., Nguyen, M., Schneider, E., Ungewiss, J., Paschke, M., Haase, C., von Hacht, J. L., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05842-5 · Cited by 283
Self-citationImaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Metadata
- Authors
- Baum, R. P., Schuchardt, C., Singh, A., Chantadisai, M., Robiller, F. C., Zhang, J., Mueller, D., Eismant, A., Almaguel, F., Zboralski, D., Osterkamp, F., Hoehne, A., Reineke, U., Smerling, C., & Kulkarni, H. R.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2021-06-24
- Volume
- 63
- Issue
- 3
- Pages
- 415-423
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W3173923097
- Cited by
- 359
- References
- 27
- FWCI
- 22.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.